258 results about "Human epidermal growth factor" patented technology

The invention discloses a serum-free culture medium for mesenchymal stem cells. The serum-free culture medium for the mesenchymal stem cells comprises the following ingredients: fibronectin at the final concentration of 25mu g/ml, basic fibroblast growth factors at the final concentration of 10ng/ml, human epidermal growth factors at the final concentration of 15ng/ml, recombinant human insulin at the final concentration of 1mg/ml, human transferrin at the final concentration of 0.55mg/ml, human blood albumin in a volume ratio of 5 percent, sodium selenite at the final concentration of 0.67mug/ml, L-carnitine at the final concentration of 5mM and resveratrol at the final concentration of 30mu M. When the mesenchymal stem cells are cultured by the serum-free culture medium for the mesenchymal stem cells, animal-derived serum is not contained, so infection risks can be controlled; the L-carnitine and the resveratrol which are added into the serum-free culture medium for the mesenchymalstem cells can effectively improve the growth state of the mesenchymal stem cells; and the growth speed of the mesenchymal stem cells is remarkably improved, and the biological characteristics of themesenchymal stem cells are kept unchanged.

Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

The invention discloses a nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of the human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain, and the extracellular binding domain, the transmembrane domain and the intracellular signal domain are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (epidermal growth factor receptor EGFR) for specific recognition of 287th-302th amino acid epitopes of EGFR.

A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.

The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen. The present invention is related to a diabody-type bispecific antibody, having a first specificity to a human epidermal growth factor (EGF) receptor and a second specificity to a surface antigen expressed by a cell having phagocytosis or cytotoxic activity, a single-chain polypeptide constituting the antibody or each region contained therein, a nucleic acid encoding the polypeptide, a replicable cloning vector or expression vector comprising the nucleic acid, a host cell transformed with the vector, and a pharmaceutical preparation comprising thereof.

This invention includes signal peptide gene phoAspL10, expression plasmid pBL10EGF, host cell of bacillus coli BL21 (DE3) inverted by expression plasmid pBL10EGF, engineering strain BE-2 screened from the host cell and preparation method of rhEGF. The strain BE-2 can excrete and express rhEGF directly into culture after fermentation and the quantity is 384mg/l.The purity is more than 95% and specific activity more than 1.0*106IU/mg protein. The product rhEGF reserves crude space configuration and shows high biological activity.

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

The invention relates to the technical field of gene recombination, in particular to a method for preparing soluble and high-activity recombinant human epidermal growth factor; the invention solves the problems that the human epidermal growth factor which is obtained by using the chemical synthesis method and the biological extraction method which have different self-defects respectively and by using the gene recombination method has lower purify and low yield and activity, and comprises the following steps of: constructing the gene cloning of the human epidermal growth factor, replacing codons which are not beneficial to be expressed by Escherichia coli to obtain optimized gene sequence, adding molecular chaperone of PDI to help target gene to be expressed effectively in Escherichia coli, and embedding HIS label and enzyme cutting site of protein in the sequence to help the target gene to be purified effectively, and the identification of biological activity; the obtained human epidermal growth factor has high purify, high yield, high activity, low cost, simple production technique and stable product quality; the product can be used for manufacturing drugs or articles for beauty and cosmetics and is beneficial to be promoted to the public.

The invention relates to the technical field of cell culture, and in particular to a serum-free culture medium, a preparation method thereof and a culture method of mesenchymal stem cells. The culturemedium consists of the following components: non-essential amino acid, glutamine, hydrocortisone, dexamethasone, polyvinyl alcohol, recombinant human insulin, recombinant human transferrin, a recombinant human epidermal growth factor, a recombinant human basic fibroblast growth factor, a recombinant human Wnt-3a protein, a recombinant human fibronectin, recombinant human laminin, L-glutathione, L-ascorbic acid, beta-mercaptoethanol, ethanolamine, Pluronic F-68, Tween 80, cholesterol, adenine, sodium selenite and a basic culture medium. According to the invention, polyvinyl alcohol can replaceserum albumin in a serum-free culture medium in carrier function, so that proliferation capacity of mesenchymal stem cells is effectively improved. Polyvinyl alcohol has more stable performance thanserum albumin, and the problem that proliferation capacity and passage capacity of stem cells are reduced can be effectively solved.

The invention relates to a polypeptide for specifically targeting a human epidermal growth factor receptor 2 (HER2) protein. The polypeptide is shown in the following general formula 1 of X1X2X3X4X5X6X7RX8YWX9X10X11X12X13X14X15X16X17RX18X19X20X21YX22. The invention also relates to a nucleotide sequence for coding the polypeptide, an expression vector for expressing the polypeptide and a host cell. The invention also relates to the polypeptide and its bivalent or multivalent, a pharmaceutical composition prepared from the polypeptide or its bivalent or multivalent as a targeting polypeptide, a preparation for killing cancer cells and a developing agent, and a use of the polypeptide and its bivalent or multivalent. The polypeptide has HER2 positive cell targeting effects and strong selectivity. The polypeptide can be prepared by a chemical synthesis method and has the advantages of high purity, small molecular weight, strong singularity, no immunogenicity, safety and reliability.

A serum-free cryoprotectant includes: 8-15 v/v% of DMSO, 85-92 v/v% of a DMEM basic culture medium, and a nutritional additive. The nutritional additive includes: fibroblast growth factors, insulin, growth hormone, transferrin, bone morphogenetic protein 4, glutamine, sodium pyruvate, beta-mercaptoethanol, human epidermal growth factor, sodium selenite, and various amino acids and vitamins. The cryoprotectant is free of animal sourced serum and avoids pollution and risk of allergen, and has better clinical safety. The serum-free cryoprotectant is suitable for cryopreservation of human placenta sourced, umbilical cord sourced and cord blood sourced mesenchymal stem cells; compared with common serum cryoprotectants, perinatal mesenchymal stem cells preserved in the cryoprotectant have high cell survival rate after resuscitation, have excellent adherence growth status and maintain biological characters well.

The invention discloses a cell culture medium. The raw material formula of the cell culture medium comprises 33.33ml of DMEM/High Glucose (DMEM high-glucose culture medium), 66.67ml of HAM'S/F-12 culture medium, 3-5mg/mL of plant-origin recombinant human serum albumin, 100U/ml of penicillin, 100 micrograms/milliliter of streptomycin, 2.5 micrograms/milliliter of amphotericin B, 0.2-0.5 micrograms/milliliter of hydrocortisone, 3-6 micrograms/milliliter of insulin, 6-10ng/ml of cholera toxin B, 9-12ng/ml of human epidermal growth factor EGF, 22-25 micrograms/milliliter of adenine, and 7-9 micromoles/liter of Y-27632. The cell culture medium can be used for culturing primary human tumor cells or tumor stem cells. The cell culture medium is improved; when the cell culture medium is applied to culturing the primary human tumor cells or the tumor stem cells, the cell culture medium is capable of better accelerating the growth of the primary tumor cells and obtaining the human tumor stem cells of a higher ratio.

The invention discloses a human epidermal growth factor nanoliposome, which contains liposome microcapsules and human epidermal growth factor wrapped in the liposome microcapsules, wherein the mass ratio of the human epidermal growth factor to the liposome microcapsules ranges from 1: 50 to 1: 200. The invention also discloses a method for preparing the human epidermal growth factor nanoliposome. Phosphatide and cholesterol are adopted as the main membrane materials, whose biomembrane-like structures are similar to the skin structure and have good transdermal permeability, and are easier to prepare a lipid carrier with a uniform particles size and high entrapment rate by a preparation technology. According to the invention, human epidermal growth factor (hEGF) is prepared into the nanoliposome. As a raw material, the nanoliposome supplemented by other biologically-active substances such as hyaluronic acid is prepared by a corresponding preparation technology into aqua, cream and emulsion skin care products, so as to rapidly repair damaged skin, repair and remove wrinkles, nurse after sunscreen and radiation examination, nurse sensitive skin, and remove and repair various scars.

The invention relates to a gel which can improve vaginal microenvironment and restore vaginal microdamage and is suitable for treatment on various kinds of vaginitis and cervicitis caused by vaginal microecological disturbance and vaginal microdamage, auxiliary treatment on vaginitis and cervicitis after clinical treatment, and treatment on cervical erosion, in particular to a cervical mucosa inducing gel which comprises carbomer, triclosan and human epidermal growth factors, wherein the concentration of the carbomer is 3%-5%, the concentration of the triclosan is 0.1%-0.6%, and the concentration of the human epidermal growth factors is 1/100000-1/10000. The cervical mucosa inducing gel can effectively improve the vaginal cleanness and increase the lactobacillus quantity to further reduce the vaginal pH value, has obvious effect on restoring cervical erosion, and can be used for auxiliary treatment on vaginitis and cervicitis after treatment.

The invention provides a nanometer bionic slow release biomedical dressing and a preparation method thereof. The nanometer bionic slow release fibrous membrane dressing is applied to providing a good microenvironment to union of wounds and promoting hemostasis, analgesia and antibiosis. The stoste of the nanometer bionic slow release biomedical dressing is aqueous liquor containing silk fibroin, human epidermal growth factors and fibroblast growth factors, and the pH value is 5-8, wherein the mass percentage concentration of silk fibroin is 2-30% and total concentration of the human epidermal growth factors and the fibroblast growth factors is 0-200ppm; or chitosan with the mass percentage concentration of 1-10% replaces the silk fibroin; the electrostatic spinning technology is adopted, so that the stoste of the nanometer bionic slow release biomedical dressing forms a spraying jet which is sprayed to a collector so as to obtain the nanometer bionic slow release biomedical dressing.

The invention relates to a serum-free medium of a human amniotic epithelial stem cell and a culture method thereof. The serum-free medium is formed by adding a human epidermal growth factor, human transferring, human insulin, sodium selenite, alanyl-L-glutamine dipeptide, alanine, asparaginate, aspartic acid, glutamic acid, glycine, proline and serine to a DMEM/F12 basic medium. The culture method comprises the steps of digesting 2.5g/L of trypsin for a human amniotic membrane, obtaining the human amniotic epithelial stem cell and filtering to prepare a single cell suspension; putting the human amniotic epithelial stem cell into a CO2 incubator of which the saturated humidity and the volume fraction are 5% at 37 DEG C through the serum-free medium under a serum-free condition and achieving growth and amplification of the amniotic epithelial stem cell through liquid exchange and subculture under the serum-free culture condition, the serum-free medium has the characteristics of stem cells, and is free of other animal sources, wide in source and free of ethical restriction.

The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.

The present invention provides a gene transfer system mediated by epidermal growth factor receptor (EGFR). It comprises (a) ligand oligopeptide specifically combined in EGFR, (b) polycation polypeptide or protein and optional (c) endocytic corpuscular release oligopeptide and (d) exogenous DNA. The described gene transfer system can effectively make the exogenous gene be target-introduced into the tumor cell expressing EGFR in vivo and in video so as to inhibit the growth of tumor.

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

The invention belongs to the field of biotechnology, especially the detection of gene mutation. More specifically, the invention discloses 9 groups of primers for detection of 41 mutation of a human epidermal growth factor EGFR gene and a detection method by using the primers.

The invention discloses an improved culture medium for neonatal pig islet cells and a use method of the same. An apoptosis inhibitor Z-VAD-FMK, a human basic fibroblast growth factor hFGF-beta, a vascular endothelial growth factor VEGF, an insulin-like growth factor R3-IGF-1, a human epidermal growth factor hEGF, a hepatocyte growth factor hHGF, pig serum, sodium selenite, insulin, transferrin, ethanol amine, 1-methyl 3-isobutyl xanthine, nicotine, cortisol, penicillin and streptomycin are added in HAM'S F10 culture medium. According to the culture medium, apoptosis can be reduced and recovery rate can be increased; the cultured cells have a sensitive glucose stimulation response and more mature functions compared with generally-cultured islet cells; the insulin secretion amount of the islet cells with the same quantity is increased; the viability of islet beta-cells is improved; the breakages of islet cell clusters are reduced, and the envelops of the cell clusters are complete, so that the cell clusters are more suitable for being transplanted.